Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels

Abstract Objective To verify glomerular PLA2R antigen and serum PLA2R antibody expression in membranous nephropathy as well as to explore glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy (IMN) in the background of different serum anti-PLA2R levels. Methods We retrospectively analyzed 155 patients who were diagnosed with IMN by kidney biopsy. Patients were divided into six groups according to their serum PLA2R antibody or glomerular PLA2R antigen positiveness and the level of serum anti-PLA2R titer. Both clinical features and pathological characteristics were recorded, and the remission time was compared among groups. Correlation between clinical figures and the anti-PLA2R titer or semi-quantity of glomerular PLA2R antigen was detected. Results A positive correlation between time to partial remission and serum anti-PLA2R titer was found. Among patients with serum anti-PLA2R titer <150 RU/ml, there were shorter remission time in negative glomerular PLA2R antigen group compared with positive glomerular PLA2R antigen, and a positive correlation between time to complete remission and semi-quantity of glomerular PLA2R antigen was found. Conclusion Both glomerular PLA2R antigen and serum anti-PLA2R play a role in disease presentation and prognosis in primary membranous nephropathy. Glomerular PLA2R antigen has a major role on disease prognosis when serum anti-PLA2R titer is less than 150RU/ml, while serum anti-PLA2R has predominant role in IMN prognosis when serum anti-PLA2R titer is above 150RU/ml.

[1]  Jiao Luo,et al.  Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  F. Huang,et al.  Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study , 2020, Renal failure.

[3]  Ying Xu,et al.  Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis , 2019, BMC Nephrology.

[4]  U. Specks,et al.  Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. , 2019, Journal of the American Society of Nephrology : JASN.

[5]  T. Moliné,et al.  Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis , 2019, Lupus.

[6]  C. Hao,et al.  Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study , 2017, BMC Nephrology.

[7]  Hai-Xia Li,et al.  Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy , 2017, Medicine.

[8]  K. Nath,et al.  A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  W. Luo,et al.  Detection and clinical significance of glomerular M‐type phospholipase A2 receptor in patients with idiopathic membranous nephropathy , 2016, Internal medicine journal.

[10]  D. Salant,et al.  Membranous Nephropathy: A Journey From Bench to Bedside. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Y. Wada,et al.  Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy , 2016, PloS one.

[12]  S. Brodsky,et al.  Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis. , 2016, Kidney international.

[13]  Hong Cheng,et al.  Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy , 2016, PloS one.

[14]  H. Debiec,et al.  Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy. , 2016, Journal of the American Society of Nephrology : JASN.

[15]  Jian-Si Li,et al.  Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy , 2016, American Journal of Nephrology.

[16]  C. Zeng,et al.  Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[17]  G. Ghiggeri,et al.  Immunology of membranous nephropathy: from animal models to humans , 2016, Clinical and experimental immunology.

[18]  V. Jha,et al.  Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. , 2015, Kidney international.

[19]  P. van Paassen,et al.  Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy , 2015, American Journal of Nephrology.

[20]  M. Haas,et al.  Anti-PLA2R-associated membranous nephropathy: a review with emphasis on diagnostic testing methods. , 2015, Clinical nephrology.

[21]  Xiaoye Zhu,et al.  Renal Phospholipase A2 Receptor in Hepatitis B Virus-Associated Membranous Nephropathy , 2015, American Journal of Nephrology.

[22]  J. Wetzels,et al.  Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. , 2015, Kidney international.

[23]  H. Debiec,et al.  Pathophysiological advances in membranous nephropathy: time for a shift in patient's care , 2015, The Lancet.

[24]  Huhai Zhang,et al.  Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis , 2015, Scientific Reports.

[25]  S. Allison.  Glomerular disease: Thrombospondin type-1 domain-containing 7A—a new player in membranous nephropathy , 2015, Nature Reviews Nephrology.

[26]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2015, The New England journal of medicine.

[27]  U. Panzer,et al.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[28]  U. Panzer,et al.  PLA2R Antibody Levels and Clinical Outcome in Patients with Membranous Nephropathy and Non-Nephrotic Range Proteinuria under Treatment with Inhibitors of the Renin-Angiotensin System , 2014, PloS one.

[29]  W. Liu,et al.  The Diagnosis Accuracy of PLA2R-AB in the Diagnosis of Idiopathic Membranous Nephropathy: A Meta-Analysis , 2014, PloS one.

[30]  E. Filippone.  Idiopathic membranous nephropathy and IgG4: an interesting relationship , 2013, Clinical nephrology.

[31]  V. Tesar,et al.  Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  L. McWilliam,et al.  Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. , 2013, Kidney international.

[33]  B. Rovin,et al.  IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression , 2013, Modern Pathology.

[34]  U. Panzer,et al.  Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. , 2012, Kidney international.

[35]  J. Wetzels,et al.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[36]  A. Magnano,et al.  Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[37]  H. Debiec,et al.  Pathogenesis of membranous nephropathy: recent advances and future challenges , 2012, Nature Reviews Nephrology.

[38]  D. Salant,et al.  Anti-phospholipase A2 receptor antibody in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[39]  H. Debiec,et al.  PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. , 2011, The New England journal of medicine.

[40]  David M. Beck,et al.  Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy , 2011 .

[41]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[42]  A. Komatsuda,et al.  Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  R. Glassock.  The therapy of idiopathic membranous glomerulonephritis. , 1991, Seminars in nephrology.